Minoxidil
FDA-approved product (tablet, oral), marketed as Loniten, Men's Rogaine, Minodyl and 9 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Alopecia
- Androgenetic alopecia
- Hypertension
- Hypotrichosis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Pyrimidine derivatives; Other dermatologicals
- FDA pharmacologic class
- Arteriolar Vasodilator FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA29.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli28.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae11.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis58.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Minoxidil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Trimetrexate GlucuronateExisting use: Other agents against amoebiasis and other protozoal diseases88.6% AI-predicted activityagainst E. coliLab records exist17 registered studies
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more87.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more86.8% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more82.2% AI-predicted activityagainst E. coli44 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives81.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Leucovorin CalciumExisting use: Osteosarcoma67.6% AI-predicted activityagainst E. coli50+ registered studies
- LevoleucovorinExisting use: Anemia, Colorectal adenocarcinoma, Colorectal cancer and 3 more67.6% AI-predicted activityagainst E. coli50+ registered studies
- PyrimethamineExisting use: Malaria, Toxoplasmosis64.6% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Copanlisib DihydrochlorideExisting use: Follicular lymphoma, Neoplasm, Neoplasm of mature B-cells63.5% AI-predicted activityagainst E. coli10 registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria62.6% AI-predicted activityagainst E. coli23 registered studies
- Rimegepant SulfateExisting use: Migraine disorder61.6% AI-predicted activityagainst E. coli50+ registered studies
- Histrelin AcetateExisting use: Neoplasm, Prostate adenocarcinoma, Prostate cancer61.6% AI-predicted activityagainst E. coli13 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia
NCT07076706 · start 2024-12-05
Registered record
- Registry ID
- NCT07076706
- Conditions
- Male Pattern of Hair Loss, Androgenic Alopecia; Androgenetic Alopecia (AGA)
- Interventions
- minoxidil + finasteride; minoxidil + finasteride; Placebo foam
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2024-12-05
- Completion
- 2025-09-23
- Enrolment
- 110
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMale Pattern of Hair Loss, Androgenic Alopecia; Androgenetic Alopecia (AGA)Interventionminoxidil + finasteride; minoxidil + finasteride; Placebo foamPhasePhase 2Registry statusCompletedEvaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
NCT05888922 · start 2024-10-17
Registered record
- Registry ID
- NCT05888922
- Conditions
- Androgenetic Alopecia; Female Pattern Baldness
- Interventions
- Minoxidil Tablets; Minoxidil Topical; Placebo oral tablet; Vehicle solution
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Active not recruiting
- Start
- 2024-10-17
- Completion
- 2026-11-16
- Enrolment
- 520
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAndrogenetic Alopecia; Female Pattern BaldnessInterventionMinoxidil Tablets; Minoxidil Topical; Placebo oral tablet; Vehicle solutionPhasePhase 3Registry statusActive not recruitingClinical Study of Probiotic Treatment for Androgenetic Alopecia
NCT06484881 · start 2024-09-15
Registered record
- Registry ID
- NCT06484881
- Conditions
- Androgenetic Alopecia; Female Pattern Baldness
- Interventions
- Daniel Alain Probiotic Treatment for Androgenetic Alopecia; Topical minoxidil 5%
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Withdrawn
- Start
- 2024-09-15
- Completion
- 2024-10-10
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAndrogenetic Alopecia; Female Pattern BaldnessInterventionDaniel Alain Probiotic Treatment for Androgenetic Alopecia; Topical minoxidil 5%PhasePhase 3Registry statusWithdrawnPhase I Clinical Trial of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia
NCT07038941 · start 2024-03-19
Registered record
- Registry ID
- NCT07038941
- Conditions
- Male Pattern of Hair Loss, Androgenic Alopecia; Androgenetic Alopecia (AGA)
- Interventions
- CG2001; Placebo foam
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2024-03-19
- Completion
- 2024-06-02
- Enrolment
- 44
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMale Pattern of Hair Loss, Androgenic Alopecia; Androgenetic Alopecia (AGA)InterventionCG2001; Placebo foamPhasePhase 1Registry statusCompletedComparison of Microneedling vs. Autologous Concentrated Growth Factor for the Treatment of Female Androgenetic Alopecia
NCT06218394 · start 2023-12-14
Registered record
- Registry ID
- NCT06218394
- Conditions
- Androgenetic Alopecia
- Interventions
- microneedling; Autologous Concentrated Growth Factor; 5% minoxidil
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2023-12-14
- Completion
- 2024-12-31
- Enrolment
- 135
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAndrogenetic AlopeciaInterventionmicroneedling; Autologous Concentrated Growth Factor; 5% minoxidilPhaseNot applicableRegistry statusUnknownHair Regeneration in Androgenetic Alopecia
NCT06066827 · start 2023-08-14
Registered record
- Registry ID
- NCT06066827
- Conditions
- Androgenetic Alopecia
- Interventions
- Minoxidil Topical; Secretome from adipose-derived stem cells; Combination of minoxidil and secretome from adipose-derived stem cells
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2023-08-14
- Completion
- 2023-11-30
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAndrogenetic AlopeciaInterventionMinoxidil Topical; Secretome from adipose-derived stem cells; Combination of minoxidil and secretome from adipose-derived stem cellsPhaseNot applicableRegistry statusUnknownToxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris
NCT06108193 · start 2023-07-11
Registered record
- Registry ID
- NCT06108193
- Conditions
- Acne Vulgaris
- Interventions
- topical minoxidil in Acne Vulgaris
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Unknown
- Start
- 2023-07-11
- Completion
- 2023-12-31
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcne VulgarisInterventiontopical minoxidil in Acne VulgarisPhasePhase 1 / Phase 2Registry statusUnknownEffectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia
NCT05990400 · start 2023-05-01
Registered record
- Registry ID
- NCT05990400
- Conditions
- Androgenetic Alopecia
- Interventions
- Finasteride; Minoxidil
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Unknown
- Start
- 2023-05-01
- Completion
- 2023-12-30
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAndrogenetic AlopeciaInterventionFinasteride; MinoxidilPhasePhase 2 / Phase 3Registry statusUnknownProof of Concept Study of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation
NCT05790941 · start 2023-03-11
Registered record
- Registry ID
- NCT05790941
- Conditions
- Hypotrichosis
- Interventions
- Latanoprost and Minoxidil
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Unknown
- Start
- 2023-03-11
- Completion
- 2023-06-30
- Enrolment
- 12
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypotrichosisInterventionLatanoprost and MinoxidilPhaseEarly phase 1Registry statusUnknownA Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors
NCT05778825 · start 2023-03-10
Registered record
- Registry ID
- NCT05778825
- Conditions
- Survivors of Childhood Cancer; Alopecia
- Interventions
- Oral Minoxidil; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2023-03-10
- Completion
- 2027-03
- Enrolment
- 10
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSurvivors of Childhood Cancer; AlopeciaInterventionOral Minoxidil; PlaceboPhasePhase 2Registry statusActive not recruitingTreatment of Androgenetic Alopecia in Men for 24 Weeks
NCT04721548 · start 2023-03-02
Registered record
- Registry ID
- NCT04721548
- Conditions
- Alopecia
- Interventions
- Minoxidil Topical Foam; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2023-03-02
- Completion
- 2024-03-06
- Enrolment
- 336
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAlopeciaInterventionMinoxidil Topical Foam; PlaceboPhasePhase 3Registry statusCompletedRole of Minoxidil in Alopecia Areata Transepidermal Drug Delivery of Minoxidil Via Either Fractional Carbon Dioxide Laser or Microneedling Versus Its Topical Nanoparticles Preparation for Treatment of Alopecia Areata
NCT05587257 · start 2023-01-01
Registered record
- Registry ID
- NCT05587257
- Conditions
- Alopecia Areata
- Interventions
- Fractional CO2 laser; Derma pen; Niosome minoxidil; Minoxidil Topical Spray
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2023-01-01
- Completion
- 2024-02-01
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAlopecia AreataInterventionFractional CO2 laser; Derma pen; Niosome minoxidil; Minoxidil Topical SprayPhaseNot applicableRegistry statusUnknownClinical Application of Stem Cell Educator Therapy in Alopecia Areata
NCT04011748 · start 2022-09-20
Registered record
- Registry ID
- NCT04011748
- Conditions
- Alopecia Areata; Alopecia Totalis; Alopecia Universalis
- Interventions
- Stem Cell Educator therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2022-09-20
- Completion
- 2023-07-30
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAlopecia Areata; Alopecia Totalis; Alopecia UniversalisInterventionStem Cell Educator therapyPhasePhase 2Registry statusUnknownRadiofrequency in Female Pattern Hair Loss
NCT05409755 · start 2022-06-25
Registered record
- Registry ID
- NCT05409755
- Conditions
- Female Pattern Baldness
- Interventions
- Vivacy
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2022-06-25
- Completion
- 2022-09-15
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFemale Pattern BaldnessInterventionVivacyPhaseNot applicableRegistry statusUnknownEvaluation of the Effect of HFMT in Promoting Donor-site Wound Healing
NCT05839158 · start 2022-03-01
Registered record
- Registry ID
- NCT05839158
- Conditions
- Wound Heal
- Interventions
- HFMT cell suspension; Mupirocin ointment
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2022-03-01
- Completion
- 2022-12-31
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionWound HealInterventionHFMT cell suspension; Mupirocin ointmentPhaseNot applicableRegistry statusCompleted